Buy Generic Daclatasvir Online

Generic Daclatasvir Information

Introduction

Daclatasvir is an oral antiviral medication indicated for the treatment of chronic hepatitis C virus (HCV) infection. It belongs to the class of direct‑acting antiviral agents (DAA) that target the HCV non‑structural protein 5A (NS5A). In Hong Kong, where HCV prevalence is estimated at .5‑1 % of the adult population, Daclatasvir is incorporated into guideline‑recommended regimens, often in combination with other DAAs such as sofosbuvir or ledipasvir. The active compound is Daclatasvir; the drug is marketed worldwide under the brand name Daklinza, and generic versions contain the identical molecule. Our online pharmacy provides this generic alternative at a price close to the manufacturer’s cost, offering an accessible option for patients who face limited insurance coverage or supply constraints.

What is Daclatasvir?

Daclatasvir is a small‑molecule inhibitor of the HCV NS5A protein, a pivotal component of the viral replication complex. The compound was discovered and developed by Bristol‑Myers Squibb and received approval from the U.S. Food and Drug Administration (FDA) in 2015 under the brand name Daklinza. Generic formulations, which contain the same active ingredient, have since been approved in the European Union, Japan, and several Asian jurisdictions, including Hong Kong.

Daclatasvir is the generic version of Daklinza, containing the same active compound Daclatasvir. Our online pharmacy provides this generic alternative as a cost‑effective treatment option.

How Daclatasvir Works

NS5A is a multifunctional phosphoprotein that anchors the HCV replication complex to intracellular membranes and regulates RNA replication and virion assembly. Daclatasvir binds to a conserved region of NS5A, causing a conformational change that disrupts the formation of the replication complex. This inhibition halts viral RNA synthesis, reduces viral load rapidly, and limits the production of infectious particles.

Key pharmacokinetic points:

• Onset: Significant reductions in HCV RNA are observed within the first week of therapy.
• Half‑life: Approximately 12‑15 hours, allowing once‑daily dosing.
• Metabolism: Primarily hepatic via CYP3A4; minimal renal excretion.
• Clearance: Hepatic clearance predominates; dose adjustment is rarely needed in mild to moderate hepatic impairment but is contraindicated in severe hepatic failure (Child‑Pugh C).

Conditions Treated with Daclatasvir

• Chronic HCV genotype 1, 2, 3, 4, and 5 infections (when combined with a complementary pan‑genotypic DAA such as sofosbuvir).
• HCV infection with compensated cirrhosis (Child‑Pugh A).
• HCV/HIV co‑infection (provided drug‑drug interactions are managed).

In Hong Kong, genotype 3 accounts for roughly 30 % of HCV cases, and the Daclatasvir‑sofosbuvir combination achieves sustained virologic response (SVR) rates above 95 % in this subgroup, according to local clinical data published in the Hong Kong Medical Journal (2022). The regimen also shortens treatment duration to 12 weeks for most patients, compared with older interferon‑based protocols that required 24‑48 weeks and carried substantial toxicity.

Patient Groups Most Likely to Benefit

• Adults with chronic HCV genotype 1‑5 who are treatment‑naïve or have previous DAA failure, provided there is no contraindicated drug interaction.
• Patients with compensated cirrhosis who require an effective, well‑tolerated oral regimen.
• Individuals with HCV/HIV co‑infection where interferon is contraindicated.
• Patients unable to tolerate ribavirin because Daclatasvir‑based regimens are ribavirin‑free.

Contra‑indicated or cautionary scenarios include:

• Severe hepatic impairment (Child‑Pugh C) – risk of accumulation.
• Concurrent use of strong CYP3A4 inducers (e.g., rifampicin, carbamazepine) – may reduce efficacy.
• Pregnant or breastfeeding women – safety data are insufficient; therapy should be delayed until after delivery when possible.

Risks, Side Effects, and Interactions

Common

• Fatigue
• Headache
• Nausea
• Diarrhea

These events are typically mild to moderate, transient, and resolve without intervention.

Rare

• Elevated transaminases (ALT/AST)
• Insomnia
• Rash (non‑urticarial)

Routine liver function monitoring is advised, especially in patients with pre‑existing liver disease.

Serious

• Hepatic decompensation (rare, primarily in patients with advanced cirrhosis).
• Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome).

Any sign of worsening jaundice, abdominal swelling, or unexplained rash warrants immediate medical evaluation.

Clinically Relevant Drug‑Drug Interactions

• Strong CYP3A4 inducers (rifampicin, St. John’s wort, carbamazepine) → ↓ Daclatasvir plasma levels → possible virologic failure.
• CYP3A4 inhibitors (ketoconazole, ritonavir‑boosted protease inhibitors) → ↑ Daclatasvir exposure → consider dose reduction to 30 mg once daily (instead of 60 mg) if co‑administered.
• Amiodarone → increased risk of bradycardia when combined with sofosbuvir/daclatasvir; cardiac monitoring recommended.
• Antacids containing aluminum or magnesium → may reduce absorption; separate dosing by at least 2 hours.

Practical Use: Dosing, Missed Dose, Overdose

• Standard adult dose: 60 mg (one tablet) taken orally once daily, preferably with food to enhance absorption.
• Renal impairment: No dose adjustment required for eGFR ≥30 mL/min/1.73 m².
• Missed dose: Take the missed tablet as soon as remembered on the same day; do not double the next dose.
• Overdose: No specific antidote. Observe the patient for prolonged gastrointestinal symptoms or hepatic enzyme elevation; provide supportive care and contact a poison‑control center if severe.

Patients should avoid grapefruit juice, which can modestly inhibit CYP3A4 and raise drug concentrations. Alcohol intake is not contraindicated but should be limited, especially in the presence of liver disease.

Buying Daclatasvir from Our Online Pharmacy

Patients in Hong Kong can purchase generic Daclatasvir directly from our online pharmacy. The service offers:

• Affordable pricing: Costs are close to the manufacturer’s wholesale price, making therapy accessible for individuals without comprehensive insurance coverage.
• Verified quality: All products are sourced from licensed, GMP‑certified manufacturers and undergo third‑party testing for potency and purity.
• Guaranteed delivery: Discreet, temperature‑controlled packaging is shipped via express courier (typically 5‑7 business days) or regular airmail (approximately 3 weeks). Tracking numbers are provided for every order.
• Online‑only access: We partner with overseas licensed pharmacies, enabling patients to obtain international medications that may not be stocked locally.

Our pharmacy operates as a broker service, facilitating safe and confidential acquisition of Daclatasvir while complying with Hong Kong’s regulatory framework. Each order is subject to a mandatory professional evaluation by an independent, licensed healthcare professional to confirm medical appropriateness before the medication is released.

FAQ

• Is Daclatasvir approved for use in Hong Kong?
  Yes, the Hong Kong regulatory authority has approved Daclatasvir (both brand‑name Daklinza and generic equivalents) for the treatment of chronic hepatitis C in combination with other DAAs.

• Can I purchase Daclatasvir without a local prescription?
  Purchasing Daclatasvir from a local pharmacy in Hong Kong requires a valid prescription. Our online service streamlines this requirement by conducting a mandatory professional evaluation. An independent, licensed healthcare professional reviews the health information you provide at checkout to ensure safety and appropriateness before a prescription is issued.

• What brand names are associated with Daclatasvir?
  The most widely recognized brand name is Daklinza. Generic versions contain the identical active compound and are marketed under the name “Daclatasvir” by several international manufacturers.

• Does Daclatasvir need refrigeration?
  No, Daclatasvir tablets are stable at room temperature (15‑30 °C). They should be stored away from direct sunlight, excessive heat, and moisture.

• How long does a typical treatment course last?
  When combined with sofosbuvir, the usual treatment duration is 12 weeks for most genotypes. Certain cirrhotic patients may require 24 weeks, as determined by the treating physician.

• Is Daclatasvir safe for patients with mild renal impairment?
  Yes, renal function does not significantly affect Daclatasvir clearance; no dose adjustment is needed for eGFR ≥ 30 mL/min/1.73 m².

• Can Daclatasvir be taken with alcohol?
  Moderate alcohol consumption is not contraindicated, but patients with liver disease should limit intake to reduce additional hepatic stress.

• Will my health insurance in Hong Kong cover Daclatasvir?
  Coverage varies among private insurers and public schemes. Some plans reimburse generic DAAs, while others may only cover brand‑name products. Patients should verify benefits with their insurer.

• What packaging does the medication arrive in?
  Orders are shipped in tamper‑evident blister packs, each containing the prescribed number of 60 mg tablets, accompanied by a sealed plastic pouch for moisture protection.

• Can I travel internationally with Daclatasvir obtained online?
  Yes, but you should carry a copy of the prescription and a physician’s letter stating the medical need. Check the destination country’s import regulations prior to travel.

• Are there any known differences in formulation between regions?
  The active ingredient is identical worldwide. However, excipients may vary slightly among manufacturers; all formulations meet international pharmacopeial standards for safety and efficacy.

Glossary

NS5A inhibitor

A class of antiviral drugs that block the hepatitis C virus non‑structural protein 5A, preventing viral replication and assembly.

Sustained virologic response (SVR)

The absence of detectable HCV RNA in the blood 12 weeks after completing therapy, considered a cure.

CYP3A4

A liver enzyme responsible for metabolizing many drugs; strong inducers or inhibitors of CYP3A4 can alter Daclatasvir levels.

Compensated cirrhosis

Advanced liver scarring where liver function remains adequately maintained (Child‑Pugh A).

⚠️ Disclaimer

The information provided about Daclatasvir is for general knowledge only. It does not replace professional medical consultation. All treatment decisions should be made under the supervision of a qualified healthcare provider. We assume all readers are responsible adults capable of making informed decisions about their health. Our online pharmacy offers access to Daclatasvir for individuals who may have limited availability through traditional pharmacies, prescription‑based insurance schemes, or who are seeking affordable generic alternatives. Always consult your doctor before starting, changing, or discontinuing any medication.